Literature DB >> 16293220

[Hepatoid adenocarcinoma of the stomach. A case report].

T Jalle1, C Gérard, P E Lada, C Sagan, J Gournay, J P Arnaud, J Paineau, A Hamy.   

Abstract

Hepatoid adenocarcinoma of the stomach is a very rare tumor with a poor prognosis. Lymph nodes involvement and/or liver metastases are frequently observed. Diagnosis should be pointed out if elevated serum level of alpha-fetoprotein (AFP) is detected with gastric tumor. Histologically, the tumor is an adenocarcinoma of intestinal type including foci of hepatoïd differenciation. Immunohistochemistry is positive for alpha-1-antitrypsin and alpha-1-antichymotripsin, and for AFP. We report a case of a 66 year-old man presenting an advanced stage of hepatoid adenocarcinoma of the stomach, treated by gastrectomy followed by chemotherapy. The patient died four months after the surgery because of progressing liver metastatic disease.

Entities:  

Mesh:

Year:  2005        PMID: 16293220     DOI: 10.1016/j.anchir.2005.08.003

Source DB:  PubMed          Journal:  Ann Chir        ISSN: 0003-3944


  4 in total

1.  Hepatoid adenocarcinoma of the stomach: a report of three cases.

Authors:  Min-Feng Ye; Feng Tao; Fang Liu; Ai-Jing Sun
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

2.  Hepatoid adenocarcinoma of the stomach: A case report and literature review.

Authors:  Xiao-Mei Liu; Gui-Qiu Chen; Shun-Li Li; Tian-Shu Zai
Journal:  Exp Ther Med       Date:  2015-03-30       Impact factor: 2.447

3.  AFP-producing hepatoid adenocarcinoma of the stomach: a case report.

Authors:  Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Sotirios Barbanis; Foteini Karasavvidou; Christos N Papandreou
Journal:  Cases J       Date:  2009-12-09

4.  The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.

Authors:  Kai Zhou; Anqiang Wang; Sheng Ao; Jiahui Chen; Ke Ji; Qifei He; Xin Ji; Xiaojiang Wu; Ji Zhang; Zhongwu Li; Zhaode Bu; Jiafu Ji
Journal:  BMC Cancer       Date:  2020-07-17       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.